On May 3, 2023 Circio Holding ASA (formerly Targovax ASA*) (OSE: TRVX) reported that an abstract describing its circular RNA platform has been accepted for poster presentation at the 2023 American Society of Gene + Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting in Los Angeles, USA (Press release, Circio, MAY 3, 2023, View Source [SID1234630907]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract describes the development of Circio’s proprietary circAde vector system for therapeutic protein expression. Key elements necessary for circRNA biogenesis were systematically screened and optimized to facilitate high yield circRNA expression. Additionally, protein expression from the circAde vector was found to outperform conventional mRNA-based designs, both in terms of protein expression level and durability in vitro. Our results highlight the potential of the circAde platform for the development of novel, more effective strategies for the treatment of diseases in which durable transgene expression is desirable.
The poster is scheduled for presentation Thursday 18 May 2023 and will be available on Circio’s website after the presentation.
Poster title: circAde, a Vector System for Spliceosome Dependent circRNA Biogenesis and Prolonged More Effective Protein Expression
Date and time: Thursday 18 May 2023, 12:00- 13:30 PDT / 21:00-22:30 CEST
Location: The Los Angeles Convention Center in Los Angeles, CA
Poster number: 1095
Presenter: Eoghan O’Leary, Director RNA Research
About ASGCT (Free ASGCT Whitepaper)
The American Society of Gene and Cell Therapy’s (ASGCT) (Free ASGCT Whitepaper) Annual Meeting is the premier event for professionals in gene and cell therapy. The meeting is the best place for people in the field to learn from the latest scientific research, stay up to date on new technologies, and make career-advancing connections with peers.
Originally designed as a venue for academic researchers to share their work, the Annual Meeting has grown to serve a wide community encompassing clinicians, bio-industry development, regulatory agencies, equipment manufacturers, patient advocates, and more.
*) Targovax ASA, which is changing its company name to Circio Holding ASA, has called for an AGM on 22 May 2023, to vote for the approval of the change of its company name from Targovax ASA to Circio Holding ASA.